Literature DB >> 31287661

DARK Classics in Chemical Neuroscience: Gamma-Hydroxybutyrate (GHB).

Trevor A Trombley1, Rory A Capstick1, Craig W Lindsley1,2,3,4.   

Abstract

Gamma-hydroxybutyrate (GHB) is a naturally occurring short-chain fatty acid that rose to prominence as a popular club drug in the 1990s. Originally developed as an anesthetic in the early 1960s, it was later sold as an over-the-counter dietary supplement before becoming a rising substance of abuse in the following decades as one of the "date rape" drugs. Despite its abuse potential, there has been a recent surge in therapeutic interest in the drug due to its clinical viability in the treatment of narcolepsy and alcohol abuse/withdrawal. Its interactions with the GABAergic framework of higher mammals has made it the prototypical example for the study of the chief inhibitory mechanism in the human central nervous system. Though relatively obscure in terms of popular culture, it has a storied history with widespread usage in therapeutic, recreational ("Chemsex"), and some disturbingly nefarious contexts. This Review aims to capture its legacy through review of the history, synthesis, pharmacology, drug metabolism, and societal impact of this DARK classic in chemical neuroscience.

Entities:  

Keywords:  GABA; GHB; Gamma-hydroxybutyrate; narcolepsy; substance abuse

Year:  2019        PMID: 31287661     DOI: 10.1021/acschemneuro.9b00336

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  2 in total

1.  Urinary Profile of Endogenous Gamma-Hydroxybutyric Acid and its Biomarker Metabolites in Healthy Korean Females: Determination of Age-Dependent and Intra-Individual Variability and Identification of Metabolites Correlated With Gamma-Hydroxybutyric Acid.

Authors:  Suji Kim; Suein Choi; Min Seo Lee; Mingyu Kim; Maria Park; Sungpil Han; Seunghoon Han; Hye Suk Lee; Sooyeun Lee
Journal:  Front Pharmacol       Date:  2022-04-13       Impact factor: 5.988

Review 2.  Toxicological Characterization of GHB as a Performance-Enhancing Drug.

Authors:  Arianna Giorgetti; Francesco Paolo Busardò; Raffaele Giorgetti
Journal:  Front Psychiatry       Date:  2022-04-18       Impact factor: 5.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.